Valo Health to Participate in Barclays and Oppenheimer Healthcare Investor Conferences

BOSTON, MA (March 1, 2021) — Valo Health LLC (Valo), the tech­nol­o­gy com­pa­ny that is using human-cen­tric data and machine learn­ing com­pu­ta­tion to trans­form and accel­er­ate the drug dis­cov­ery and devel­op­ment process, announced today that its CEO and founder, David Berry, will present at the fol­low­ing investor con­fer­ences in March: 

Event: Bar­clays Glob­al Health­care Conference

Date/​Time: Tues­day, March 9, 2021 at 8:00 a.m. EST

Event: Oppen­heimer’s 31st Annu­al Health­care Conference 

Date/​Time: Tues­day, March 16, 2021 8:40 a.m. EST

A replay of the Bar­clays web­cast will be avail­able on the Valo LinkedIn page and the Valo web­site after the event.

Con­tacts:

Investors: Graeme Bell, Chief Finan­cial Officer

gbell@​valohealth.​com

Media:

Jen­nifer Han­ley, VP Cor­po­rate Communications

jhanley@​valohealth.​com

About Valo

Valo Health, LLC (Valo) is a tech­nol­o­gy com­pa­ny that is using human-cen­tric data and machine learn­ing com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process. As a dig­i­tal­ly native com­pa­ny, Valo is the first to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life­cy­cle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing the cost, time, and fail­ure rate. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­formTM, a ful­ly inte­grat­ed, com­pu­ta­tion­al, end-to-end drug devel­op­ment plat­form, offers a unique approach to ther­a­peu­tic devel­op­ment that enables Valo to advance a robust pipeline of can­di­dates across car­dio­vas­cu­lar dis­ease, oncol­o­gy, and neu­rode­gen­er­a­tion. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo has offices in Lex­ing­ton, MA, San Fran­cis­co, CA, Prince­ton, NJ, and in Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.


Other
Press